Dual-signal-independent chimeric antigen receptors and uses thereof

A chimeric antigen receptor and dual-signal technology, which can be used in antibody mimics/scaffolds, medical preparations containing active ingredients, fusion with soluble cell surface receptors, etc., can solve the problem of decreased therapeutic efficacy

Active Publication Date: 2021-08-13
SHANGHAI CELL THERAPY GRP CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, CAR + The "cascade" effect caused by off-target T cells is very fast, and these suicide systems may not be able to function in time
Another approach is to reduce CAR + The number of T cells reinfused, this program will reduce the efficacy of treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual-signal-independent chimeric antigen receptors and uses thereof
  • Dual-signal-independent chimeric antigen receptors and uses thereof
  • Dual-signal-independent chimeric antigen receptors and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0034] The terms "chimeric antigen receptor" in the present invention are artificial transformation receptors, which can be anchored to immunocytes (such as T cells) that identify a specific molecule (such as antibody) that recognizes tumor antigens, enabling immunocytes to identify tumor antigen or viruses. Antigen and killing tumor cells or viral infections.

[0035] The term "T cell activation correlation signal" in the present invention refers to the first signal of the T cell surface TCR-CD3 complex and antigenic peptide-MHC molecule to provide T cell activation, and provide T cell activation. The killing specificity of T cells; a co-stimulator (e.g., CD28) of the T cell surface (such as CD28) is bonded to the corresponding ligand (such as B7), providing a second signal activated by T cells, promoting T cell activation, proliferation and survival.

[0036] The terms "ImmunorePtor Tyrosine-BasedActivation Motifes, ITAM) refers to immunocytocytes activated receptors such as BCR...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a chimeric antigen receptor (CAR), especially a dual-signal independent chimeric antigen receptor, and also relates to an immune response cell expressing the CAR, and the immune response cell is used for preparing and treating malignant tumors and Use in medicine for viral infectious diseases. Specifically, the dual-signal-independent CAR recognizes antigens from two different families of tumor cells, respectively, and transmits two signals related to T cell activation. One of the CARs transmits the first signal related to T cell activation by binding to tumor-specific antigens or ligands of tumor-associated antigens, which determines the killing specificity of T cells; the other CAR binds to membrane receptors widely expressed by tumor cells (such as The ligand of EGFR family member protein) transmits the second signal related to T cell activation and promotes T cell activation, proliferation and survival. The present invention can avoid the potential safety problems on the basis of maintaining the curative effect of the second-generation and third-generation CARs.

Description

Technical field [0001] The present invention relates to a chimeric anoblast receptor, in particular a two-signal independent chimeric antigen receptor, and the present invention also relates to immunoreactive cells expressing the chimeric antigens receptor, and the immune response cells for preparation treatment. Use of malignant tumors and viral infectious diseases. Background technique [0002] Adoptive Cell therapy, ACT is a method of retransmitting the treated autologous or allogeneic immune cells (mainly autologous cells) to tumor patients to enhance the patient's immune function to achieve the purpose of treatment. The current tumor ACT has progressed rapidly, and the translatable immunotherapy for tumor-infiltrating lymphocyte, TIL has achieved a very good clinical effect against melanoma (Science 2002; 298: 850-4). However, T cell activation requires both signal stimulation, namely two T cell activation related signals. Among them, the T cell surface TCR-CD3 complex is bo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N5/10A61K48/00A61P31/12A61P35/00
CPCA61K38/177A61P31/12A61P35/00C07K14/7051C07K14/7056C07K16/3092C07K2317/622C07K2319/00C07K2319/32
Inventor 钱其军金华君丁娜俞德超李林芳吴孟超
Owner SHANGHAI CELL THERAPY GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap